Source: Annual Congress 2012 - The many roads to lung injury
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A.K. Neuhauß, B. Gutbier, T. Friedemann, A. Günther, D. Stoll, N. Weißmann, T.J. Mitchell, H. Schütte, N. Suttorp, M. Witzenrath, Capnetz Study Group (Berlin, Konstanz, Gießen, Hanover, Germany; Glasgow, United Kingdom). Angiopoietins: Possible biomarkers in severe pneumonia?. Eur Respir J 2012; 40: Suppl. 56, 830

Member's Comments

No comment yet.

Related content which might interest you: Platelets: a potential role in chronic respiratory diseases? Source: Eur Respir Rev, 30 (161) 210062; 10.1183/16000617.0062-2021 Year: 2021 Procalcitonin as etiological marker of severe community-acquired pneumonia Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013 Known and emerging risk factors for asthma development: is prevention possible? Source: International Congress 2015 – Asthma: emerging risk factors and current management of the patient Year: 2015 Role of biomarkers of systemic inflammation in the prediction of mortality and/or severe complications in community adquired pneumonia Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Targeting coagulation activation in severe COVID-19 pneumonia: lessons from bacterial pneumonia and sepsis Source: Eur Respir Rev, 29 (157) 200240; 10.1183/16000617.0240-2020 Year: 2020 Acute exacerbation in patients with bronchiectasis: What prognostic factors? Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Potential new biomarkers for idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Late Breaking Abstract - An assessment of potential predictive biomarkers for the treatment of severe eosinophilic asthma with CRTH2 antagonists Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Risk factors of pulmonary NTM disease in COPD: how bad are glucocorticoids? Source: International Congress 2014 – The rise in non-tuberculous mycobacteria (NTM) pulmonary diseases Year: 2014 Treatment failure of community-acquired pneumonia: risk factors and consequences Source: Annual Congress 2012 - PG17 Clinical failure of treatment of respiratory infections Year: 2012 Biomarkers and VAP: results and perspectives Source: Eur Respir Mon 2011; 53: 24-35 Year: 2011 Accuracy of inflammatory markers to distinguish between pneumonia and pulmonary embolism in acute settings Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Recurrence predictive factors of cryptogenic organizing pneumonia Source: International Congress 2015 – Connective tissue disorders Year: 2015 Features of systemic inflammation in patients with severe community-acquired (CAP) pneumonia of different etiology in HIV-infected patients Source: International Congress 2015 – Immunodepression and severe pneumonia Year: 2015 Endothelial microparticles in sputum of COPD patients: A potential biomarker of disease Source: International Congress 2015 – Systemic and airway biomarkers Year: 2015 Potential angiogenic biomarkers in patients with non small cell lung cancer: Possible implications Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Clinical pneumonia: how do I make a specific diagnosis? Source: Virtual Congress 2021 – The "State of the Art" in the diagnosis of bacterial, mycobacterial, and fungal pneumonias Year: 2021